Alpha Tau Medical (DRTS) Expected to Announce Earnings on Wednesday

Key Points

• Alpha Tau Medical (DRTS) is set to announce its Q2 2025 earnings on August 13th, with analysts expecting a loss of ($0.12) per share.
• The company's previous earnings results, reported on May 19th, showed a loss of ($0.12) per share, beating expectations of ($0.14) by $0.02.
• HC Wainwright has maintained a "buy" rating for Alpha Tau Medical and set a price target of $9.00 per share.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 13th. Analysts expect Alpha Tau Medical to post earnings of ($0.12) per share for the quarter.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last posted its earnings results on Monday, May 19th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. On average, analysts expect Alpha Tau Medical to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Alpha Tau Medical Price Performance

NASDAQ:DRTS traded up $0.12 during mid-day trading on Friday, hitting $3.39. The stock had a trading volume of 96,722 shares, compared to its average volume of 46,499. The company has a 50 day simple moving average of $3.05 and a 200-day simple moving average of $2.95. Alpha Tau Medical has a 52 week low of $2.06 and a 52 week high of $4.39. The company has a current ratio of 5.81, a quick ratio of 5.81 and a debt-to-equity ratio of 0.10.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and issued a $9.00 price objective on shares of Alpha Tau Medical in a research report on Tuesday, April 29th.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.